4.3 Article

Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials

期刊

LEUKEMIA & LYMPHOMA
卷 -, 期 -, 页码 -

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2023.2234528

关键词

Relapsed; refractory diffuse large B cell lymphoma; salvage chemotherapy; CAR-T therapy; >

向作者/读者索取更多资源

The optimal salvage chemotherapy regimen and the efficacy of chimeric antigen receptor T cell (CAR-T) therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) remain uncertain. A network meta-analysis showed that rituximab with gemcitabine, dexamethasone, cisplatin (R-GDP) improved overall survival (OS) and progression-free survival (PFS) compared to other salvage chemotherapy regimens. Another analysis of CAR-T trials demonstrated that both axi-cel and liso-cel improved PFS compared to standard-of-care, with no difference in OS. These findings suggest that R-GDP may be preferred for relapsed/refractory DLBCL, but longer follow-up and comparative survival analysis of CAR-T data are needed to confirm these results.
The optimal salvage chemotherapy regimen (SC) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) prior to autologous stem cell transplant remains unclear. Moreover, although chimeric antigen receptor T cell (CAR-T) therapies were recently approved for primary refractory DLBCL, head-to-head comparisons are lacking. We searched MEDLINE, EMBASE and CENTRAL to July 2022, for randomized trials that enrolled adult patients with R/R DLBCL and performed network meta-analyses (NMA) to assess the efficacy of SC and CAR-T therapies. NMA of SC (6 trials, 7 regimens, n = 1831) indicated that rituximab with gemcitabine, dexamethasone, cisplatin (R-GDP) improved OS and PFS over compared regimens. NMA of 3 CAR-T trials (n = 865) indicated that both axi-cel and liso-cel improved PFS over stand-of-care, with no difference in OS. Our results indicate that R-GDP may be preferred for R/R DLBCL over other SC compared. Longer follow-up is required for ongoing comparative survival analysis as data from CAR-T trials matures.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据